|
|
||||||||
Eur J Cardiothorac Surg 2002;22:978-983
© 2002 Elsevier Science NL
Cardiopulmonary Research Science and Technology Institute (CRSTI), 7777 Forest Lane, Suite A323, Dallas, TX 75230, USA
Received 18 September 2001; received in revised form 27 August 2002; accepted 13 September 2002.
* Corresponding author. Tel.: +1-972-566-4866; fax: +1-972-490-5457
e-mail: mjmack{at}earthlink.net
| Abstract |
|---|
|
|
|---|
Key Words: Video-assisted thymectomy Thymectomy Myasthenia gravis Thoracoscopic thymectomy
| 1. Introduction |
|---|
|
|
|---|
The purpose of this report is to provide the results in a larger group of patients with longer-term follow-up so that a more firm assessment of the approach can be made. Because of the heterogeneity of the disease and variable course, comparison of the results of different approaches is difficult, if not impossible. In an attempt to rectify this problem, the Task Force of the Myasthenia Gravis Foundation of America (MGFA) has published new classifications for clinical status, therapy status, and postintervention status [4]. Accordingly, we have classified our current patients and reclassified our earlier patients according to these guidelines to serve as a benchmark for comparison by future studies.
| 2. Materials and methods |
|---|
|
|
|---|
Our surgical technique has been well described elsewhere [1,2]. Although some evolution of the technique has occurred over the years, the principles have remained the same. We now routinely use the right-sided approach with four thoracoscopic ports (210 mm and 25 mm) with carbon dioxide insufflation, a complete resection of all anterior mediastinal tissue, extubation in the operating room, and no intensive care unit utilization. We have also extended our patient selection criteria to patients not traditionally candidates including elderly patients
55 years, with long-standing, refractory disease.
Preoperative clinical staging was assessed by the newly recommended MGFA clinical classification (Table 1). Treatment mortality and morbidity was analyzed by the MGFA morbidity and mortality criteria (Table 2). Clinical status at follow-up was assessed by the MGFA postintervention status classification (Table 3). All patients who were assessed and operated upon before the new staging system, were restaged.
|
|
|
| 3. Results |
|---|
|
|
|---|
|
|
|
| 4. Discussion |
|---|
|
|
|---|
Experience with the video-assisted approach for thymectomy in myasthenia gravis is still limited with only relatively small experience from a few centers published. Mineo et al. have reported a 96% improvement rate at 48 months in 31 patients by a left-sided approach [5]. The same group has also described the same approach for a completion thymectomy in eight patients after a previous transternal or transcervical approach [6]. More recently Gramone et al. have reported an infra-mammary video-assisted approach in 71 patients with an 80% clinical remission rate at 12 months [7]. A technique by Takeo et al. for video-assisted extended thymectomy has also been recently reported [8].
We presented our early experience by a predominately left thoracoscopic approach in 1996 as part of a multi-center experience. In our 33 patients (13 of our own) we reported an 18% remission rate and an 88% improvement rate at a mean follow-up of 23 months. We further updated our experience of 20 patients at a mean of 20 months follow-up with an 85% improvement rate in 1998 [2]. We now present our complete experience over a 10-year period. In 38 patients at a mean follow-up of 41 months, our complete remission rate is 14% and clinical improvement rate 83%. We have previously published a meta-analysis of outcomes by various techniques [2]. At follow-up periods ranging from a mean of 3675 months, complete remission rates range from 17 to 52% and clinical improvement from 57 to 97%. Although overall improvement rate in myasthenia symptoms after VATS thymectomy in our series seems to be equivalent to the more invasive approaches, we are aware that the complete stable remission (CSR) still seems to be somewhat lower. There can be a number of explanations for this, including the more strict and precise classification of CSR status by the new classification and inclusion of more elderly patients with more advanced disease. Further validation of this approach for thymectomy, however, awaits long-term follow-up and accurate comparison to outcomes of the more traditional approaches using new assessment guidelines.
However, the complexity of myasthenia gravis in pathologic findings, clinical presentation, course of the disease and response to treatment makes objective assessment difficult. There was a need for universally accepted classifications and methods of analysis for patients undergoing therapy for MG in order to achieve more uniformity and objectivity in outcome analysis. The Task Force of the MGFA developed new guidelines for clinical research standards [3]. The MGFA clinical classification (Table 1) in combination with Quantitative MG Score for Disease Severity provides a more objective and quantitative assessment of the disease. The MGFA postintervention status classification (Table 3) provides precise and detailed assessment of treatment outcomes. We feel that strict adherence to the newly recommended MGFA classification should accomplish more precise reporting of post-treatment outcomes in myasthenia patients, and thus increase the accuracy of statistical comparisons between the studies.
Based on our experience we have eliminated the need for an intensive care unit for postoperative care and have begun to perform the procedure in an outpatient setting. In addition, because of the minimal morbidity associated with the procedure, we have begun to offer thymectomy to patients not traditionally considered candidates for thymectomy due to advanced age, long-standing disease, and without detectable thymic tissue by preoperative scanning. We have experienced the ability to improve the clinical status and reduce the steroid regimen in a few of these refractory patients.
Comparison of results of different therapeutic approaches is only possible with standardized classification and reporting. As such, we have classified the preoperative clinical status of all our patients, the operative mortality and morbidity, and the postintervention status by the MGFA task force guidelines. When the results of experience in other centers are reported by the same standardized criteria with the various surgical approaches, we may be better able to determine the efficacy of the various surgical approaches.
| Footnotes |
|---|
| Appendix A. Conference discussion |
|---|
|
|
|---|
Dr Savcenko: We had six thymomas in the whole series. In the first 20 patients there were six enlarged, 13 patients who didn't have any. Preoperatively all patients are evaluated by CT scan the same as for any open procedure before surgery as far as you can say staging of thymoma is concerned. They were all encapsulated, very small stage I thymomas by Masaoka's classification. Of course, until you take it out and have evaluated the specimen by gross and histologic examination can one determine how extensive is the resection, we can evaluate it just the same as with an open thymectomy from the time back when you evaluate it after you remove the thymus and all anterior mediastinal tissue and from the specimen, what you get out. So evaluation is actually the same. So we are very confident that we are getting it all.
You never know, even in open procedure, if you get all extra-anatomic microscopic thymic tissue, the same way you will never know in the VATS procedure. But the same principle applies for both approaches: do complete thymectomy and do maximal exenteration of all anterior mediastinal tissue.
Dr T. Grodzki (Szczecin, Poland): It was a very nice presentation and good advertising of a new classification, but I couldn't see any specific advantages of this new classification over the old ones. You didn't compare them. Could you comment on that?
Dr Savcenko: Absolutely. There is not enough time to go through this whole comprehensive booklet of this new classification. Most importantly, the authors hope that this classification would become more uniformly used as opposed to presently not so uniformly used various different preoperative classifications like the Osserman classification, modified Osserman and Genkins classification or Oosterhuis classification.
Secondly, I did not have the slide on this because there is not enough time. Very important is the quantitative evaluation. Quantitative scoring would supplement those main categories I showed you. In order to put patients in class I, class II, class III, you have to not only evaluate just which muscle group is involved, but there is precise, very precise indication about the severity of muscle weakness. So this would give you a quantitative evaluation. Those are the most important points.
Dr R. Schmid (Bern, Switzerland): We are also very interested in this new approach and we performed it. On the other side we carefully looked at our old data with 13 years of follow-up. Two questions: 20 or 25% of complete remission is not the same as the 3040% which were achieved with the open approach. It is not proven at all that the results are the same in respect to complete remission, and complete remission I think is the main issue we have to look at. An improvement of 80% is okay and comparable to the old data, but we observed that the results in almost all studies in the literature deteriorate over time, and we therefore have to look at long-term outcome. I think we should avoid a premature conclusion. Thoracoscopy is an excellent approach, cosmetically good, and more patients might accept the operation, but we cannot say at the moment that the results of the thoracoscopic approach are the equal of the open technique.
Dr Savcenko: Absolutely not, and unfortunately we cannot do a randomized study. There are not enough patients so that you could randomize them for either approach. In the old classification we would probably have up to a 35% incomplete state of remission, but by this new classification it is much lower because it is much more strict. But I agree with you. As I showed in the last slide, time alone will tell. There are still only 41 months of follow-up. Five years and more would be really necessary to have some real conclusions for that.
Professor A. Yim (Shatin, Hong Kong): I rise to congratulate the Dallas group to be among one of the first to use this new MGFA Clinical Classification. This is a very detailed classification system meant to be used prospectively. Did you encounter much difficulty trying to apply this retrospectively on your patients who already had surgery?
Dr Savcenko: Absolutely. That is an excellent question. It doesn't make any sense to have a strict classification and not have enough information about it. In those retrospective studies like this and when we go back, from now on it will be much easier because everything will be routed in this classification. It took us a lot of time through the neurologists, patients, of course, and medical records to go back and precisely detail what was done 8 years ago. From now on it will be much easier. But that is an excellent question.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. Toker, S. Tanju, S. Ziyade, S. Kaya, and S. Dilege Learning curve in videothoracoscopic thymectomy: how many operations and in which situations? Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 155 - 158. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Tomulescu, V. Ion, A. Kosa, O. Sgarbura, and I. Popescu Thoracoscopic thymectomy mid-term results. Ann. Thorac. Surg., September 1, 2006; 82(3): 1003 - 1007. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Manlulu, T. W. Lee, I. Wan, C. Y. Law, C. Chang, J. C. Garzon, and A. Yim Video-Assisted Thoracic Surgery Thymectomy for Nonthymomatous Myasthenia Gravis Chest, November 1, 2005; 128(5): 3454 - 3460. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Savitt, G. Gao, A. P. Furnary, J. Swanson, H. L. Gately, and J. R. Handy Application of Robotic-Assisted Techniques to the Surgical Evaluation and Treatment of the Anterior Mediastinum Ann. Thorac. Surg., February 1, 2005; 79(2): 450 - 455. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |